3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
320
Leukemia, Myeloid, Acute
266
Multiple Myeloma
227
Carcinoma, Non-Small-Cell Lung
224
Prostatic Neoplasms
202
Neoplasms
196
Lymphoma
191
Colorectal Neoplasms
184
Melanoma
179
Leukemia
170
Recurrence
164
Pancreatic Neoplasms
163
Precursor Cell Lymphoblastic Leukemia-Lymphoma
160
Lung Neoplasms
150
Glioblastoma
134
Neoplasm Metastasis
132
Lymphoma, Non-Hodgkin
128
Ovarian Neoplasms
123
Leukemia, Lymphocytic, Chronic, B-Cell
120
Myelodysplastic Syndromes
117
Lymphoma, Large B-Cell, Diffuse
110
Lymphoma, Mantle-Cell
108
Carcinoma, Hepatocellular
103
Lymphoma, Follicular
99
Stomach Neoplasms
96
Carcinoma, Renal Cell
89
Hodgkin Disease
88
Brain Neoplasms
88
Sarcoma
84
Burkitt Lymphoma
75
Interventions
palbociclib
1
aumolertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
OTHER
×
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
×
Clear all
NCT06947811
2025-06-04
APEAK
Sun Yat-sen University
Phase 1/2
Recruiting
71 enrolled